As the top frequent alterations in the overall population, amplifications in FGF3/4/19 (490, 4.0%) occurred the most in esophagus cancer (60/159, 37.7%), head and neck carcinoma (54/257, 21.0%), and urinary tract cancer (41/275, 14.9%), and were the least in pancreatic cancer (4/635, 0.6%), sarcoma (2/369, 0.5%), and ovarian cancer (1/293, 0.3%). Here, FGF3 is linked to sarcoma.